Ascendiant Capital Markets Increases RenovoRx (NASDAQ:RNXT) Price Target to $8.25

RenovoRx (NASDAQ:RNXT) had its price target increased by equities researchers at Ascendiant Capital Markets from $8.00 to $8.25 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock.

RenovoRx Stock Up 5.2 %

NASDAQ RNXT opened at $1.13 on Thursday. The company has a market cap of $27.00 million, a price-to-earnings ratio of -1.56 and a beta of 0.98. RenovoRx has a 52 week low of $0.53 and a 52 week high of $2.35. The business has a 50 day moving average price of $1.13 and a 200-day moving average price of $1.24.

RenovoRx (NASDAQ:RNXT) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.10) EPS for the quarter.

Institutional Investors Weigh In On RenovoRx

An institutional investor recently bought a new position in RenovoRx stock. Nixon Peabody Trust Co. purchased a new position in shares of RenovoRx, Inc. (NASDAQ:RNXT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 97,165 shares of the company’s stock, valued at approximately $223,000. Nixon Peabody Trust Co. owned approximately 0.91% of RenovoRx at the end of the most recent quarter. Institutional investors and hedge funds own 3.10% of the company’s stock.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.